Regulators of platelet camp levels: Clinical and therapeutic implications

Current Medicinal Chemistry

Volumn 17, Issue 26, 2010, Pages 2897-2905

  Noe L ^a   Peeters, K ^a   Izzi, B ^a   van Geet, C ^a,b   Freson, K ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

cAMP; G protein coupled receptor; P2Y12antagonist; Prostacyclin; Pulmonary arterial hypertension; Regulator of G protein signaling

Indexed keywords

ACETYLSALICYLIC ACID; ADENYLATE CYCLASE; BERAPROST; CANGRELOR; CARDIOVASCULAR AGENT; CLOPIDOGREL; CYCLIC AMP; ILOPROST; PRASUGREL; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN E RECEPTOR; PURINERGIC P2Y12 RECEPTOR ANTAGONIST; TICLOPIDINE; UNCLASSIFIED DRUG; UNIPROST; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

ACUTE CORONARY SYNDROME; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; HEMOSTASIS; HUMAN; NONHUMAN; PROTEIN PROTEIN INTERACTION; PULMONARY HYPERTENSION; THROMBOCYTE AGGREGATION;

BLOOD PLATELETS; CYCLIC AMP; HUMANS; HYPERTENSION, PULMONARY; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; SIGNAL TRANSDUCTION; TICLOPIDINE;

EID: 77955646166     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710792065018     Document Type: Article

References (58)

1. Offermanns, S. Activation of platelet function through G protein-coupled receptors. Circ. Res., 2006, 99, 1293-1304.
2. Yang, J.; Wu, J.; Jiang, H.; Mortensen, R.; Austin, S.; Manning, D. R.; Woulfe, D.; Brass, L. F. Signaling through Gi family members in platelets. Redundancy and specificity in the regulation of adenylyl cyclase and other effectors. J. Biol. Chem., 2002, 277, 46035-46042.
3. van Willigen, G.; Donath, J.; Lapetina, E. G.; Akkerman, J. W. Identification of alpha-subunits of trimeric GTP-binding proteins in human platelets by RT-PCR. Biochem. Biophys. Res. Commun., 1995, 214, 254-262.
4. Freson, K.; Jaeken, J.; Van Helvoirt, M.; de Zegher, F.; Wittev-rongel, C.; Thys, C.; Hoylaerts, M. F.; Vermylen, J.; Van Geet, C. Functional polymorphisms in the paternally expressed XLalphas and its cofactor ALEX decrease their mutual interaction and enhance receptor-mediated cAMP formation. Hum. Mol. Genet., 2003, 12, 1121-1130.
5. Feijge, M. A.; Ansink, K.; Vanschoonbeek, K.; Heemskerk, J. W. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3. Biochem. Pharmacol., 2004, 67, 1559-1567.
6. Schwarz, U. R.; Walter, U.; Eigenthaler, M. Taming platelets with cyclic nucleotides. Biochem. Pharmacol., 2001, 62, 1153-1161.
7. Cavallini, L.; Coassin, M.; Borean, A.; Alexandre, A. Prostacyclin and sodium nitroprusside inhibit the activity of the platelet inositol 1,4,5-trisphosphate receptor and promote its phosphorylation. J. Biol. Chem., 1996, 271, 5545-5551.
8. Butt, E.; Abel, K.; Krieger, M.; Palm, D.; Hoppe, V.; Hoppe, J.; Walter, U. cAMP- and cGMP-dependent protein kinase phosphory-lation sites of the focal adhesion vasodilator-stimulated phos-phoprotein (VASP) in vitro and in intact human platelets. J. Biol. Chem., 1994, 269, 14509-14517.
9. Lerea, K. M.; Glomset, J. A. Agents that elevate the concentration of cAMP in platelets inhibit the formation of a NaDodSO4-resistant complex between thrombin and a 40-kDa protein. Proc. Natl. Acad. Sci. U.S.A., 1987, 84, 5620-5624.
10. Watson, S. P.; McConnell, R. T.; Lapetina, E. G. The rapid formation of inositol phosphates in human platelets by thrombin is inhibited by prostacyclin. J. Biol. Chem., 1984, 259, 13199-13203.
11. Cheng, Y.; Austin, S. C.; Rocca, B.; Koller, B. H.; Coffman, T. M.; Grosser, T.; Lawson, J. A.; FitzGerald, G. A. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science, 2002, 296, 539-541.
12. Ledent, C.; Vaugeois, J. M.; Schiffmann, S. N.; Pedrazzini, T.; El Yacoubi, M.; anderhaeghen, J. J.; Costentin, J.; Heath, J. K.; Vas-sart, G.; Parmentier, M. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature, 1997, 388, 674-678.
13. Murugappa, S.; Kunapuli, S. P. The role of ADP receptors in platelet function. Front. Biosci., 2006, 11, 1977-86.
14. Gagnon, A. W.; Murray, D. L.; Leadley, R. J. Cloning and characterization of a novel regulator of G protein signalling in human platelets. Cell. Signal., 2002, 14, 595-606.
15. Roy, A. A.; Baragli, A.; Bernstein, L. S.; Hepler, J. R.; Hebert, T. E.; Chidiac, P. RGS2 interacts with Gs and adenylyl cyclase in living cells. Cell. Signal., 2006, 18, 336-348.
16. Kim, S. D.; Sung, H. J.; Park, S. K.; Kim, T. W.; Park, S. C.; Kim, S. K.; Cho, J. Y.; Rhee, M. H. The expression patterns of RGS transcripts in platelets. Platelets, 2006, 17, 493-497.
17. Freson, K.; Hashimoto, H.; Thys, C.; Wittevrongel, C.; Danloy, S.; Morita, Y.; Shintani, N.; Tomiyama, Y.; Vermylen, J.; Hoylaerts, M. F.; Baba, A.; Van Geet, C. The pituitary adenylate cyclase-activating polypeptide is a physiological inhibitor of platelet activation. J. Clin. Invest., 2004, 113, 905-912.
18. Miyata, A.; Arimura, A.; Dahl, R. R.; Minamino, N.; Uehara, A.; Jiang, L.; Culler, M. D.; Coy, D. H. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem. Biophys. Res. Commun., 1989, 164, 567-574.
19. Freson, K.; Peeters, K.; De Vos, R.; Wittevrongel, C.; Thys, C.; Hoylaerts, M. F.; Vermylen, J.; Van Geet, C. PACAP and its receptor VPAC1 regulate megakaryocyte maturation: therapeutic implications. Blood, 2008, 111, 1885-1893.
20. Andre, P.; Delaney, S. M.; LaRocca, T.; Vincent, D.; DeGuzman, F.; Jurek, M.; Koller, B.; Phillips, D. R.; Conley, P. B. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J. Clin. Invest., 2003, 112, 398-406.
21. Hollopeter, G.; Jantzen, H. M.; Vincent, D.; Li, G.; England, L.; Ramakrishnan, V.; Yang, R. B.; Nurden, P.; Nurden, A.; Julius, D.; Conley, P. B. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature, 2001, 409, 202-227.
22. Cattaneo, M.; Zighetti, M. L.; Lombardi, R.; Martinez, C.; Lecchi, A.; Conley, P. B.; Ware, J.; Ruggeri, Z. M. Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding. Proc. Natl. Acad. Sci. U.S.A., 2003, 100, 1978-1983.
23. Fabre, J. E.; Nguyen, M.; Athirakul, K.; Coggins, K.; McNeish, J. D.; Austin, S.; Parise, L. K.; FitzGerald, G. A.; Coffman, T. M.; Koller, B. H. Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. J. Clin. Invest., 2001, 107, 603-610.
24. Ma, H.; Hara, A.; Xiao, C. Y.; Okada, Y.; Takahata, O.; Nakaya, K.; Sugimoto, Y.; Ichikawa, A.; Narumiya, S.; Ushikubi, F. Increased bleeding tendency and decreased susceptibility to throm-boembolism in mice lacking the prostaglandin E receptor subtype EP(3). Circulation, 2001, 104, 1176-1180.
25. Gross, S.; Tilly, P.; Hentsch, D.; Vonesch, J. L.; Fabre, J. E. Vascular wall-produced rostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptors. J. Exp. Med., 2007, 204, 311-320.
26. Heptinstall, S.; Espinosa, D. I.; Manolopoulos, P.; Glenn, J. R.; White, A. E.; Johnson, A.; Dovlatova, N.; Fox, S. C.; May, J. A.; Hermann, D.; Magnusson, O.; Stefansson, K.; Hartman, D.; Gurney, M. DG-041 inhibits the EP3 prostanoid receptor-- a new target for inhibition of platelet function in atherothrombotic disease. Platelets, 2008, 19, 605-613.
27. Singh, J.; Zeller, W.; Zhou, N.; Hategen, G.; Mishra, R.; Polozov, A.; Yu, P.; Onua, E.; Zhang, J.; Zembower, D.; Kiselyov, A.; Ramirez, J. L.; Sigthorsson, G.; Bjornsson, J. M.; Thorsteinsdottir, M.; Andresson, T.; Bjarnadottir, M.; Magnusson, O.; Fabre, J. E.; Stefansson, K.; Gurney, M. E. Antagonists of the EP(3) receptor for prostaglandin E(2) are novel antiplatelet agents that do not prolong bleeding. ACS Chem. Biol., 2009.
28. Peters, J.; Wroe, S. F.; Wells, C. A.; Miller, H. J.; Bodle, D.; Beechey, C. V.; Williamson, C. M.; Kelsey, G. A cluster of oppositely imprinted transcripts at the Gnas locus in the distal imprinting region of mouse chromosome 2. Proc. Natl. Acad. Sci. U.S.A., 1999, 96, 3830-3835.
29. Liu, J.; Yu, S.; Litman, D.; Chen, W.; Weinstein, L. S. Identification of a methylation imprint mark within the mouse Gnas locus. Mol. Cell Biol., 2000, 20, 5808-5817.
30. Coombes, C.; Arnaud, P.; Gordon, E.; Dean, W.; Coar, E. A.; Williamson, C. M.; Feil, R.; Peters, J.; Kelsey, G. Epigenetic properties and identification of an imprint mark in the Nesp-Gnasxl domain of the mouse Gnas imprinted locus. Mol. Cell Biol., 2003, 23, 547-588.
31. Plagge, A.; Kelsey, G.; Germain-Lee, E. L. Physiological functions of the imprinted Gnas locus and its protein variants Galpha(s) and XLalpha(s) in human and mouse. J. Endocrinol., 2008, 196, 193-214.
32. Kelsey, G.; Bodle, D.; Miller, H. J.; Beechey, C. V.; Coombes, C.; Peters, J.; Williamson, C. M. Identification of imprinted loci by methylation-sensitive representational difference analysis: application to mouse distal chromosome 2. Genomics, 1999, 62, 129-138.
33. Freson, K.; Izzi, B.; Labarque, V.; Van Helvoirt, M.; Thys, C.; Wittevrongel, C.; Bex, M.; Bouillon, R.; Godefroid, N.; Proesmans, W.; de Zegher, F.; Jaeken, J.; Van Geet, C. GNAS defects identified by stimulatory G protein alpha-subunit signalling studies in platelets. J. Clin. Endocrinol. Metab., 2008, 93, 4851-4859.
34. Freson, K.; Hoylaerts, M. F.; Jaeken, J.; Eyssen, M.; Arnout, J.; Vermylen, J.; Van Geet, C. Genetic variation of the extra-large stimulatory G protein alpha-subunit leads to Gs hyperfunction in platelets and is a risk factor for bleeding. Thromb. Haemost., 2001, 86, 733-738.
35. Pasolli, H. A.; Klemke, M.; Kehlenbach, R. H.; Wang, Y.; Huttner, W. B. Characterization of the extra-large G protein alpha-subunit XLalphas. I. Tissue distribution and subcellular localization. J. Biol. Chem., 2000, 275, 33622-33632.
36. Klemke, M.; Pasolli, H. A.; Kehlenbach, R. H.; Offermanns, S.; Schultz, G.; Huttner, W. B. Characterization of the extra-large G protein alpha-subunit XLalphas. II. Signal transduction properties. J. Biol. Chem., 2000, 275, 33633-33640.
37. Sinnarajah, S.; Dessauer, C. W.; Srikumar, D.; Chen, J.; Yuen, J.; Yilma, S.; Dennis, J. C.; Morrison, E. E.; Vodyanoy, V.; Kehrl, J. H. RGS2 regulates signal transduction in olfactory neurons by attenuating activation of adenylyl cyclase III. Nature, 2001, 409, 1051-1055.
38. Katsel, P. L.; Tagliente, T. M.; Schwarz, T. E.; Craddock-Royal, B.; Patel, N. D.; Maayani, S. Molecular and biochemical evidence for the presence of type III adenylyl cyclase in human platelets. Platelets, 2003, 14, 21-33.
39. Noe, L.; Di Michele, M.; Giets, E.; Thys, C.; Wittevrongel, C.; De Vos, R.; Overbergh, L.; Waelkens, E.; Jaeken, J.; Van Geet, C.; Freson, K. Platelet Gs hypofunction and abnormal morphology due to a heterozygous RGS2 mutation. J. Thromb. Haemost., in press.
40. Humbert, M.; Nurden, P.; Bihour, C.; Pasquet, J. M.; Winckler, J.; Heilmann, E.; Savi, P.; Herbert, J. M.; Kunicki, T. J.; Nurden, A. T. Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation. Arterioscler. Thromb. Vasc. Biol., 1996, 16, 1532-1543.
41. Savi, P.; Herbert, J. M. Clopidogrel and ticlopidine: P2Y12 adeno-sine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin. Thromb. Hemost., 2005, 31, 174-183.
42. Savi, P.; Herbert, J. M.; Pflieger, A. M.; Dol, F.; Delebassee, D.; Combalbert, J.; Defreyn, G.; Maffrand, J. P. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem. Pharmacol., 1992, 44, 527-532.
43. Gurbel, P. A.; Bliden, K. P.; Hiatt, B. L.; O'Connor, C. M. Clopi-dogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation, 2003, 107, 2908-2913.
44. Simon, T.; Verstuyft, C.; Mary-Krause, M.; Quteineh, L.; Drouet,; Meneveau, N.; Steg, P. G.; Ferrieres, J.; Danchin, N.; Bec-quemont, L. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med., 2009, 360, 363-375.
45. Mega, J. L.; Close, S. L.; Wiviott, S. D.; Shen, L.; Hockett, R. D.; Brandt, J. T.; Walker, J. R.; Antman, E. M.; Macias, W.; Braun- wald, E.; Sabatine, M. S. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med., 2009, 360, 354-362.
46. Wallentin, L.; Varenhorst, C.; James, S.; Erlinge, D.; Braun, O. O.; Jakubowski, J. A.; Sugidachi, A.; Winters, K. J.; Siegbahn, A. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur. Heart J., 2008, 29, 21-30.
47. Jernberg, T.; Payne, C. D.; Winters, K. J.; Darstein, C.; Brandt, J. T.; Jakubowski, J. A.; Naganuma, H.; Siegbahn, A.; Wallentin, L. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur. Heart J., 2006, 27, 1166-1173.
48. Brandt, J. T.; Close, S. L.; Iturria, S. J.; Payne, C. D.; Farid, N. A.; Ernest, C. S., 2nd; Lachno, D. R.; Salazar, D.; Winters, K. J. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J. Thromb. Haemost., 2007, 5, 2429-2436.
49. Storey, R. F.; Oldroyd, K. G.; Wilcox, R. G. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb. Haemost., 2001, 85, 401-407.
50. Husted, S.; Emanuelsson, H.; Heptinstall, S.; Sandset, P. M.; Wickens, M.; Peters, G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur. Heart J., 2006, 27, 1038-1047.
51. JJ, V. A. N. G.; Nilsson, L.; Berntsson, P.; Wissing, B. M.; Gior-danetto, F.; Tomlinson, W.; Greasley, P. J. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost, 2009, 7, 1556-1565.
52. Wallentin, L.; Becker, R. C.; Budaj, A.; Cannon, C. P.; Emanuels-son, H.; Held, C.; Horrow, J.; Husted, S.; James, S.; Katus, H.; Mahaffey, K. W.; Scirica, B. M.; Skene, A.; Steg, P. G.; Storey, R. F.; Harrington, R. A.; Freij, A.; Thorsen, M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med., 2009, 361, 1045-1057.
53. Stewart, S.; Rassl, D. Advances in the understanding and classification of pulmonary hypertension. Histopathology, 2009, 54, 104-116.
54. Olschewski, H.; Olschewski, A.; Rose, F.; Schermuly, R.; Schutte, H.; Weissmann, N.; Seeger, W.; Grimminger, F. Physiologic basis for the treatment of pulmonary hypertension. J. Lab. Clin. Med.,2001, 138, 287-297.
55. Christman, B. W.; McPherson, C. D.; Newman, J. H.; King, G. A.; Bernard, G. R.; Groves, B. M.; Loyd, J. E. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med., 1992, 327, 70-75.
56. Mubarak, K. K. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir. Med., 2009.
57. Gomberg-Maitland, M.; Olschewski, H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur. Respir. J., 2008, 31, 891-901.
58. Ward, I. PGI(2) receptor agonist demonstrates efficacy in pulmonary arterial hypertension. Expert Rev. Cardiovasc. Ther., 2009, 7,1193.